 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis, OC-001 / Ocellaris Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of envafolimab plus lenvatinib combined with etoposide in recurrent ovarian, peritoneal, and fallopian tube cancer: An open-label, single-arm study () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5983;
P2
The combination of envafolimab plus lenvatinib combined with etoposide shows promising efficacy and manageable toxicities in patients with platinum-resistant ovarian cancer. Clinical trial information: NCT05422183.
- || OC-001 / Ocellaris Pharma
Phase classification, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (clinicaltrials.gov) - Nov 28, 2023
P1/2, N=80, Recruiting, Sponsor: Ocellaris Pharma, Inc.
Clinical trial information: NCT05422183. Phase classification: P1b/2a --> P1/2 | Trial completion date: Nov 2022 --> Sep 2026 | Trial primary completion date: Nov 2022 --> Mar 2026
- | OC-001 / Ocellaris Pharma
Journal: Intravaginal Gel for Sustained Delivery of Occidiofungin and Long-Lasting Antifungal Effects. (Pubmed Central) - Oct 27, 2023
A gel formulation containing occidiofungin (OCF001) is being developed for use to treat vulvovaginal candidiasis...In this study, the gel formulation was shown to reduce the drug substance rate of diffusion across a skin memetic membrane. The study showed that the formulation extends exposure time to inhibitory concentrations of occidiofungin over a 24-h period and supports a single daily application for the treatment of RVVC.
- OC-001 / Ocellaris Pharma
A phase Ib dose escalation study of CD137 mAb agonist OC-001 as monotherapy in patients with advanced or metastatic cancer (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2220;
P1b/2a
The mAb has predicable PK characteristics. OC-001 is a potential candidate for combination therapy with immune-oncology agents.
- ||| OC-001 / Ocellaris Pharma
Enrollment open, Combination therapy, Monotherapy, Metastases: A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (clinicaltrials.gov) - Aug 21, 2020
P1b/2a, N=80, Recruiting, Sponsor: Ocellaris Pharma, Inc.
OC-001 is a potential candidate for combination therapy with immune-oncology agents. Not yet recruiting --> Recruiting
- || OC-001 / Ocellaris Pharma
Trial initiation date, Combination therapy, Monotherapy, Metastases: A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (clinicaltrials.gov) - Jun 23, 2020
P1b/2a, N=80, Not yet recruiting, Sponsor: Ocellaris Pharma, Inc.
Not yet recruiting --> Recruiting Initiation date: Apr 2020 --> Aug 2020